Opportunity Information: Apply for RFA DK 11 007
Apply for RFA DK 11 007
- The National Institutes of Health in the food and nutrition health income security and social services sector is offering a public funding opportunity titled "Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Feb 18, 2011 and posted on Feb 4, 2011.
- Applicants must submit their applications by Apr 4, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- The number of recipients for this funding is limited to 10 candidate(s).
- Eligible applicants include: For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities County governments Independent school districts City or township governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Organizations) are not eligible to apply Foreign (non U.S.) components of U.S. Organizations are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03)" (Funding Opportunity Number RFA-DK-11-007) is a National Institutes of Health (NIH) funding announcement designed to support early, practical groundwork for future clinical trials in type 1 diabetes. The core goal is to fund small, focused feasibility studies that directly prepare investigators to run full clinical trials aimed at improving blood glucose control and/or preventing, treating, or reducing complications related to type 1 diabetes. The emphasis is on improving real-world management and treatment for people with type 1 diabetes in the United States, with the expectation that downstream trial results would be clinically useful and ready for near-immediate application in routine care if the intervention proves effective.
This program uses the NIH R03 mechanism, which generally supports short-term, limited-scope projects. In this case, the R03 is specifically positioned as a bridge to a larger, definitive clinical trial by helping researchers answer the kinds of questions that can make or break a trial before it starts. Typical feasibility issues include whether a target population can be recruited and retained, whether randomization and study procedures are workable in real clinical settings, whether adherence to an intervention is realistic, whether outcome measures are practical and sensitive enough, and whether study logistics, staffing, and data collection workflows can function reliably. In other words, the FOA is about de-risking and strengthening the design of a future clinical trial, not running the full trial under this award.
A key boundary of the announcement is what it is not meant to do. The FOA explicitly states that it is not intended to validate new technologies or test new therapeutics. That means applicants should not frame the project as an early-stage evaluation of a novel device, platform, or drug development effort. Instead, the focus should be on feasibility and trial-readiness for interventions that can plausibly move straight into a clinically meaningful trial, with outcomes that matter to patient management and can translate quickly into practice.
From a funding and scale perspective, NIH anticipated making about 10 awards under this announcement, with an estimated total funding level of $1,000,000. The award ceiling listed is $50,000, which signals that projects must be tightly scoped and strongly focused on the specific feasibility questions that will enable a subsequent clinical trial. There is no cost sharing or matching requirement, which reduces barriers for applicants who may not have non-federal funds available to support the work.
The opportunity is categorized as discretionary and uses the grant funding instrument type. It falls under activity areas that include food and nutrition, health, income security, and social services, reflecting the broader public health and clinical management context of diabetes. The associated CFDA numbers are 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.865 (Child Health and Human Development Extramural Research), indicating the NIH institutes and program areas most closely tied to the funding stream and scientific mission.
Eligibility is broad and includes many types of U.S.-based organizations. Eligible applicants include for-profit organizations (including small businesses), nonprofit organizations (including those with or without 501(c)(3) status), private and public institutions of higher education, and a wide range of government entities such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. Tribal governments and tribal organizations are also included, with distinctions for federally recognized tribal governments versus other tribal organizations. The FOA also identifies additional eligible applicant categories such as historically black colleges and universities (HBCUs), tribally controlled colleges and universities (TCCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign organizations (non-U.S. entities) are not eligible to apply; however, foreign components of U.S. organizations are allowed, which can matter for studies involving specialized expertise, data coordination, or collaboration outside the United States while keeping the applicant organization domestic.
Timeline information shows the FOA was posted February 4, 2011, created February 18, 2011, and had an application due date of April 4, 2011. It was later archived on May 5, 2011. While these dates indicate the specific announcement is historical, the description still reflects a common NIH approach: using small feasibility awards to improve the quality, efficiency, and success rate of subsequent clinical trials in a high-impact disease area.
For further details, the full announcement was hosted on the NIH grants site at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-11-007.html. For access or technical issues, the listed point of contact was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03) - RFA-DK-11-007
What is the purpose of this grant opportunity?
This NIH funding opportunity supports small, focused feasibility studies that generate practical groundwork for a future, full-scale clinical trial in type 1 diabetes. The aim is to improve readiness for trials intended to improve blood glucose control and/or prevent, treat, or reduce type 1 diabetes-related complications.
What is the official title and funding opportunity number?
The opportunity is titled "Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03)" and the Funding Opportunity Number is RFA-DK-11-007.
Which agency is offering this funding?
The funding announcement is offered by the National Institutes of Health (NIH).
What type of NIH mechanism does this use?
This program uses the NIH R03 mechanism, which is generally intended for short-term, limited-scope projects. In this case, the R03 is positioned as a bridge to a larger, definitive clinical trial by addressing key feasibility and trial-readiness questions.
What kinds of studies are a good fit under this FOA?
Studies that directly prepare investigators to run a future clinical trial in type 1 diabetes by answering practical feasibility questions. Examples of the kinds of issues highlighted include the ability to recruit and retain the target population, whether randomization and study procedures work in real clinical settings, whether adherence is realistic, whether outcome measures are practical and sensitive enough, and whether logistics like staffing and data collection workflows function reliably.
Is this grant intended to fund a full clinical trial?
No. The intent is to fund feasibility work that de-risks and strengthens the design of a subsequent clinical trial. It is not meant to support running the full definitive trial under this award.
What is the main emphasis of the program in terms of impact?
The emphasis is on improving real-world management and treatment for people with type 1 diabetes in the United States, with an expectation that downstream clinical trial results would be clinically useful and ready for near-immediate application in routine care if the intervention is effective.
What does the FOA say the grant is not intended to do?
The FOA explicitly states it is not intended to validate new technologies or test new therapeutics. Applicants should not frame the project as early-stage evaluation of a novel device, platform, or drug development effort.
What is the funding instrument type and funding category?
The opportunity uses the grant funding instrument type and is categorized as discretionary.
How many awards were anticipated and what was the estimated total funding?
NIH anticipated making about 10 awards under this announcement, with an estimated total funding level of $1,000,000.
What is the award ceiling?
The listed award ceiling is $50,000, indicating projects must be tightly scoped and focused on the specific feasibility questions that enable a subsequent clinical trial.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
What activity areas does this opportunity fall under?
The activity areas listed include food and nutrition, health, income security, and social services, reflecting the broader public health and clinical management context of diabetes.
What CFDA numbers are associated with this funding opportunity?
The associated CFDA numbers are 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.865 (Child Health and Human Development Extramural Research).
Who is eligible to apply?
Eligibility is broad and includes many types of U.S.-based organizations. Eligible applicants include for-profit organizations (including small businesses), nonprofit organizations (including those with or without 501(c)(3) status), private and public institutions of higher education, and government entities such as state, county, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. The FOA includes tribal governments (federally recognized) and other tribal organizations among eligible applicants.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are included in the eligibility categories listed.
Are foreign organizations eligible to apply?
No. Foreign organizations (non-U.S. entities) are not eligible to apply.
Are foreign components allowed?
Yes. While the applicant organization must be U.S.-based, foreign components of U.S. organizations are allowed. This can matter for collaborations or specialized expertise outside the United States while keeping the applicant domestic.
Does the FOA highlight any specific institution types as eligible?
Yes. The FOA lists additional eligible applicant categories including historically black colleges and universities (HBCUs), tribally controlled colleges and universities (TCCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
When was this funding opportunity posted and when were applications due?
The FOA was posted on February 4, 2011. The application due date was April 4, 2011.
Is this announcement still active?
No. The opportunity was archived on May 5, 2011, indicating it is a historical announcement.
Where can I find the full announcement text?
The full announcement was hosted on the NIH grants site at http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-11-007.html.
Who was listed as the contact for access or technical issues?
The listed point of contact for access or technical issues was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the intended pathway after completing an R03 feasibility study under this FOA?
The R03 is described as a bridge to a larger, definitive clinical trial. The feasibility work is meant to address issues that can make or break the future trial, strengthening the trial design and operational approach before launching the larger study.
What kinds of operational questions does NIH expect feasibility studies to address?
The FOA highlights practical questions such as recruitment and retention in the target population, whether randomization and study procedures are workable in real clinical settings, whether adherence to the intervention is realistic, whether outcome measures are practical and sensitive enough, and whether logistics like staffing and data collection workflows can be executed reliably.
What disease area is the focus?
The focus is type 1 diabetes, specifically clinical trial preparation work aimed at improving blood glucose control and/or preventing, treating, or reducing complications associated with type 1 diabetes.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services
Next opportunity: Development of National and Regional Approaches to Environmentally Sound Management of Mercury in Southeast Asia
Previous opportunity: Impact Evaluation of Combination HIV Prevention Interventions in PEPFAR Countries
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 11 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 11 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Trial Planning Grants in Type 1 Diabetes (R34) Apply for RFA DK 11 010 Funding Number: RFA DK 11 010 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 11 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.